{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sapanisertib&page=2", "query": { "intervention": "sapanisertib", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 43, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sapanisertib&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=sapanisertib&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-01T02:11:20.817Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03097328", "title": "Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "TAK-228", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bradley A. McGregor, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2017-08-01", "completion_date": "2024-04-24", "has_results": true, "last_update_posted_date": "2024-04-29", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 8, "location_summary": "La Jolla, California • Aurora, Colorado • Chicago, Illinois + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03097328" }, { "nct_id": "NCT02893930", "title": "Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neuroendocrine Tumor G1", "Pancreatic Neuroendocrine Tumor G2", "Refractory Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2017-04-28", "completion_date": "2022-12-21", "has_results": true, "last_update_posted_date": "2023-10-17", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 405, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 260 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02893930" }, { "nct_id": "NCT02724020", "title": "MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clear-cell Metastatic Renal Cell Carcinoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" }, { "name": "MLN0128", "type": "DRUG" }, { "name": "MLN1117", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2016-06-30", "completion_date": "2020-10-13", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 7, "location_summary": "Los Angeles, California • Venice, Florida • West Palm Beach, Florida + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Venice", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02724020" }, { "nct_id": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Bladder Carcinoma", "Breast Carcinoma", "Cervical Carcinoma", "Colon Carcinoma", "Colorectal Carcinoma", "Endometrial Carcinoma", "Esophageal Carcinoma", "Exocrine Pancreas Carcinoma", "Gastric Carcinoma", "Glioma", "Head and Neck Carcinoma", "Hematopoietic and Lymphoid Cell Neoplasm", "Kidney Carcinoma", "Liver Carcinoma", "Lung Carcinoma", "Lymphoma", "Malignant Uterine Corpus Neoplasm", "Malignant Uterine Neoplasm", "Melanoma", "Multiple Myeloma", "Ovarian Carcinoma", "Prostate Carcinoma", "Rectal Carcinoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Cervical Carcinoma", "Recurrent Colon Carcinoma", "Recurrent Colorectal Carcinoma", "Recurrent Esophageal Carcinoma", "Recurrent Gastric Carcinoma", "Recurrent Glioma", "Recurrent Head and Neck Carcinoma", "Recurrent Liver Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Malignant Uterine Corpus Neoplasm", "Recurrent Melanoma", "Recurrent Multiple Myeloma", "Recurrent Ovarian Carcinoma", "Recurrent Pancreatic Carcinoma", "Recurrent Prostate Carcinoma", "Recurrent Rectal Carcinoma", "Recurrent Skin Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma", "Skin Carcinoma", "Thyroid Gland Carcinoma" ], "interventions": [ { "name": "Adavosertib", "type": "DRUG" }, { "name": "Afatinib", "type": "DRUG" }, { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Binimetinib", "type": "DRUG" }, { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Copanlisib", "type": "DRUG" }, { "name": "Copanlisib Hydrochloride", "type": "DRUG" }, { "name": "Crizotinib", "type": "DRUG" }, { "name": "Cytology Specimen Collection Procedure", "type": "OTHER" }, { "name": "Dabrafenib", "type": "DRUG" }, { "name": "Dabrafenib Mesylate", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Defactinib", "type": "DRUG" }, { "name": "Defactinib Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Erdafitinib", "type": "DRUG" }, { "name": "Fexagratinib", "type": "DRUG" }, { "name": "Ipatasertib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Larotrectinib", "type": "DRUG" }, { "name": "Larotrectinib Sulfate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Pertuzumab", "type": "BIOLOGICAL" }, { "name": "PI3K-beta Inhibitor GSK2636771", "type": "DRUG" }, { "name": "Radiologic Examination", "type": "PROCEDURE" }, { "name": "Radionuclide Imaging", "type": "PROCEDURE" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Sunitinib Malate", "type": "DRUG" }, { "name": "Taselisib", "type": "DRUG" }, { "name": "Trametinib", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Emtansine", "type": "BIOLOGICAL" }, { "name": "Ulixertinib", "type": "DRUG" }, { "name": "Vismodegib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6452, "start_date": "2015-08-17", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 1405, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465060" }, { "nct_id": "NCT02244463", "title": "A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Thyroid Cancer", "Thyroid Cancer", "Differentiated Thyroid Cancer" ], "interventions": [ { "name": "MLN0128", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2015-07", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2024-01-12", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 3, "location_summary": "Newport Beach, California • Boston, Massachusetts • Ann Arbor, Michigan", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02244463" }, { "nct_id": "NCT02719691", "title": "Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Solid Tumors" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" }, { "name": "MLN0128", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 47, "start_date": "2016-05-13", "completion_date": "2020-03-18", "has_results": true, "last_update_posted_date": "2022-07-25", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT02719691" }, { "nct_id": "NCT02503722", "title": "Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Recurrent Lung Non-Small Cell Carcinoma", "Stage III Lung Non-Small Cell Cancer AJCC v7", "Stage IIIA Lung Non-Small Cell Cancer AJCC v7", "Stage IIIB Lung Non-Small Cell Cancer AJCC v7", "Stage IV Lung Non-Small Cell Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2017-03-23", "completion_date": "2027-02-28", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 3, "location_summary": "New Haven, Connecticut • Tampa, Florida", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02503722" }, { "nct_id": "NCT01899053", "title": "A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Nonhematologic Malignancies" ], "interventions": [ { "name": "TAK-228", "type": "DRUG" }, { "name": "TAK-117", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 101, "start_date": "2013-06-28", "completion_date": "2018-04-30", "has_results": true, "last_update_posted_date": "2019-10-30", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Nashville, Tennessee • San Antonio, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01899053" }, { "nct_id": "NCT02601209", "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Sarcoma", "Metastatic Leiomyosarcoma", "Metastatic Malignant Peripheral Nerve Sheath Tumor", "Metastatic Synovial Sarcoma", "Metastatic Undifferentiated Pleomorphic Sarcoma", "Metastatic Unresectable Sarcoma", "Myxofibrosarcoma", "Recurrent Leiomyosarcoma", "Recurrent Malignant Peripheral Nerve Sheath Tumor", "Recurrent Synovial Sarcoma", "Recurrent Undifferentiated Pleomorphic Sarcoma", "Stage III Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IV Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8", "Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8", "Unresectable Leiomyosarcoma" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Pazopanib Hydrochloride", "type": "DRUG" }, { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 151, "start_date": "2015-11-30", "completion_date": "2022-07-11", "has_results": true, "last_update_posted_date": "2022-08-23", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 460, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 286 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601209" }, { "nct_id": "NCT04250545", "title": "Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leptomeningeal Neoplasm", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Neoplasm in the Brain", "Recurrent Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Telaglenastat Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2020-10-26", "completion_date": "2026-11-21", "has_results": true, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-10-01T02:11:20.817Z", "location_count": 7, "location_summary": "Duarte, California • Irvine, California • Los Angeles, California + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04250545" } ] }